KeyBanc analyst Paul Knight maintained a Buy rating on Harvard Bioscience (HBIO – Research Report) today and set a price target of $5.00. The company’s shares closed yesterday at $2.42.
Knight covers the Healthcare sector, focusing on stocks such as Azenta, Harvard Bioscience, and West Pharmaceutical Services. According to TipRanks, Knight has an average return of 1.7% and a 41.96% success rate on recommended stocks.
Harvard Bioscience has an analyst consensus of Moderate Buy, with a price target consensus of $5.00.
See today’s best-performing stocks on TipRanks >>
Based on Harvard Bioscience’s latest earnings release for the quarter ending June 30, the company reported a quarterly revenue of $29.21 million and a net profit of $2.44 million. In comparison, last year the company earned a revenue of $29.2 million and had a GAAP net loss of $410 thousand
Based on the recent corporate insider activity of 32 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of HBIO in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Harvard Bioscience, Inc. develops, manufactures, and markets broad range of specialized products, primarily apparatus and scientific instruments. It operates under the geographical segments: United States, Germany, United Kingdom, and Rest of the world. It sells its products through catalog, Website, distributors, and direct sales force. The company was founded by Dr. William T. Porter in 1901 and is headquartered in Holliston, MA.
Read More on HBIO:
